WHO ICTRP trial
An open-label, dose escalation, phase I study to evaluate the tolerability…
JPRN-jRCT2080222524 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080222524 |
|---|---|
| Public title | An open-label, dose escalation, phase I study to evaluate the tolerability, safety and pharmacokinetics of afuresertib monotherapy and in combination with bortezomib and dexamethasone in Japanese relapsed multiple myeloma patients. |
| Scientific title | An open-label, dose escalation, phase I study to evaluate the tolerability, safety and pharmacokinetics of afuresertib monotherapy and in combination with bortezomib and dexamethasone in Japanese relapsed multiple myeloma patients. |
| Primary sponsor | Novartis |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Countries | Japan |
| Conditions | Multiple Myeloma |
| Interventions | investigational material(s) Generic name etc : GSK2110183 INN of investigational material : Afuresertib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Up to 200 mg, PO, QD… |
| Registration date | Jun 17, 2014 |
| Target size | 18 |
| Secondary IDs | NCT02177682;JapicCTI-142575 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: